Inhaled Corticosteroids and Combination Controller Therapy

Asthma is predominantly a type 2 immune-mediated disease. Inhaled allergens or other triggers cause airway epithelial cells to release interleukin-25, interleukin-33, and thymic stromal lymphopoietin, which activate type 2 innate lymphoid cells. These innate lymphoid cells produce interleukin-4, interleukin-5, and interleukin-13 independently of antigen stimulation. Interleukin-5 drives eosinophil maturation, recruitment, and survival; interleukin-4 and interleukin-13 promote IgE production, goblet cell metaplasia, and airway smooth muscle hyperresponsiveness; mast cell degranulation in response to allergen-IgE crosslinking releases histamine and cysteinyl leukotrienes, producing acute bronchoconstriction.

Inhaled corticosteroids suppress this cascade at its core. They reduce transcription of type 2 cytokine genes, suppress innate lymphoid cell activity, impair eosinophil survival, and stabilize mast cells. Because the driving pathology is cytokine-dependent and glucocorticoid-sensitive, inhaled corticosteroids produce large, consistent reductions in eosinophilic inflammation, exacerbation frequency, and airway hyperresponsiveness — making them first-line controller therapy for all but the mildest asthma.

COPD is driven by a distinctly different process — primarily neutrophilic and macrophage-mediated inflammation triggered by cigarette smoke and noxious particles. The characteristic cellular infiltrate includes neutrophils, macrophages, and CD8-positive cytotoxic T lymphocytes, with few eosinophils in most patients. Neutrophil recruitment is driven by interleukin-8 and leukotriene B4; macrophage-driven proteolytic destruction of alveolar walls underlies emphysema. These processes are far less sensitive to glucocorticoids than the type 2 eosinophilic response, predicting the consistently smaller effect size of inhaled corticosteroids in COPD.

A clinically important subset of COPD patients does have elevated blood eosinophils, and this subgroup derives substantially greater benefit from inhaled corticosteroids. Blood eosinophil count is now the standard biomarker for predicting inhaled corticosteroid benefit in COPD: counts of 300 cells per microliter or higher predict meaningful exacerbation reduction; counts below 100 cells per microliter predict little benefit and increased pneumonia risk. This eosinophil threshold-guided approach is embedded in current GOLD guidelines.

Oral candidiasis is the most common local adverse effect. Topical glucocorticoids suppress local immune defenses in the oropharynx, reducing clearance of Candida albicans. Prevention is straightforward: rinsing the mouth with water and gargling after each inhaled corticosteroid dose, then spitting, removes deposited drug and substantially reduces incidence. Spacer use further reduces oropharyngeal deposition. Established oral candidiasis is treated with topical antifungals (clotrimazole or nystatin) or oral fluconazole for persistent cases.

Dysphonia (hoarseness) affects up to 30% of patients on regular inhaled corticosteroid therapy. The mechanism differs from oral candidiasis: dysphonia results from glucocorticoid-induced myopathy of the intrinsic laryngeal muscles rather than from surface drug deposition, so oropharyngeal rinsing does not reliably prevent it. Dose reduction, switching to a spacer, or choosing ciclesonide (with its lower oropharyngeal deposition) are the management options for susceptible patients, particularly professional voice users.

Hypothalamic-pituitary-adrenal axis suppression is the most clinically significant systemic adverse effect. Systemically absorbed inhaled corticosteroids suppress corticotropin-releasing hormone and adrenocorticotropic hormone secretion, reducing endogenous cortisol production. At standard low-to-medium doses, suppression is generally subclinical. At high doses — particularly above the equivalent of 1000 micrograms per day of fluticasone propionate — clinically meaningful suppression occurs, and patients face risk of secondary adrenal insufficiency during physiological stress such as surgery or major illness if inhaled corticosteroids are abruptly discontinued.

Bone mineral density reduction is a dose-dependent long-term effect. Glucocorticoids impair osteoblast function, increase osteoclast activity, and reduce intestinal calcium absorption. The magnitude is substantially smaller than with equivalent systemic corticosteroid doses, but patients on high-dose inhaled corticosteroids for prolonged periods — particularly postmenopausal women and older men — should have bone density monitored and receive supplemental calcium and vitamin D. Growth suppression in children has been demonstrated at approximately 1.2 centimeters of adult height reduction with budesonide in the Childhood Asthma Management Program trial, an effect that must be weighed against the developmental consequences of inadequately treated asthma.

The IMPACT trial enrolled more than 10,000 patients with moderate-to-very-severe COPD and at least one exacerbation in the prior year, comparing single-inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol) against dual combinations. Triple therapy reduced moderate and severe exacerbations by 25% relative to long-acting beta-2 agonist/long-acting muscarinic antagonist and by 15% relative to inhaled corticosteroid/long-acting beta-2 agonist. However, confirmed pneumonia rates were higher in both fluticasone furoate-containing arms than in the bronchodilator-only arm. The TRILOGY trial confirmed a 23% exacerbation reduction with single-inhaler triple therapy over inhaled corticosteroid/long-acting beta-2 agonist dual therapy in severe COPD.

Blood eosinophil count is now the primary biomarker guiding inhaled corticosteroid decisions in COPD. Counts of 300 cells per microliter or higher predict consistent exacerbation-reduction benefit from inhaled corticosteroid-containing regimens and support triple therapy in patients with recurrent exacerbations on dual bronchodilator therapy. Counts between 100 and 300 cells per microliter suggest intermediate benefit; inhaled corticosteroid addition is considered individually based on exacerbation frequency and severity. Counts below 100 cells per microliter predict little if any benefit and carry increased pneumonia risk — inhaled corticosteroids should generally be withheld or withdrawn in this group.

Step-up in asthma is triggered by persistent symptoms despite current therapy, one or more severe exacerbations in the past year, or reliever use more than twice weekly. Before stepping up, confirm the diagnosis, check inhaler technique, and assess adherence — these are the most common reasons for apparent treatment failure. Step-down should be considered after at least three months of sustained well-controlled asthma, beginning with inhaled corticosteroid dose reduction of approximately 25 to 50% before considering removal of add-on agents.